Milestone Pharmaceuticals Inc. (MIST)

Market Cap	87.17M
Revenue (ttm)	1,000,000
Net Income (ttm)	-59.69M
Shares Out	53.15M
EPS (ttm)	-1.39
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	27,970
Open	1.650
Previous Close	1.630
Day's Range	1.610 - 1.700
52-Week Range	1.330 - 4.490
Beta	1.77
Analysts	Buy
Price Target	11.75 (+616.46%)
Earnings Date	May 9, 2024

About MIST

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 47
• Stock Exchange: NASDAQ
• Ticker Symbol: MIST

Financial Performance

In 2023, MIST's revenue was $1.00 million, a decrease of -80.00% compared to the previous year's $5.00 million. Losses were -$59.69 million, 2.22% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for MIST stock is "Buy." The 12-month stock price forecast is $11.75, which is an increase of 616.46% from the latest price.

Price Target

$11.75

(616.46% upside)

Analyst Consensus: Buy